Targeting selective inhibitors of PARPs in drug discovery and development

Abstract

Poly(ADP-ribose)polymerases (PARPs) have emerged as promising targets for the treatment of diseases, particularly in cancers, due to their significant biological functions involved in DNA damage. As a result, researchers worldwide have made substantial advances in this field. However, studies have revealed that PARPs inhibitors lack selectivity due to the conserved domain, limiting their clinical applications and emphasizing the need for selective inhibitors. In this perspective, we summarize the recent advancements in PARPs inhibitors, with a focus on selective inhibitors among PARP family. We discuss the designed strategy, structure-activity relationships, and crystal structure, while explaining the underlying mechanisms of selectivity, hoping to provide insights for the design of next generation of PARPs selective inhibitors.